CATIONIC PEPTIDE LACTOFERRICIN B INHIBITS GLUTATHIONE S-TRANSFERASE P1 FROM HUMAN PLACENTA AND BREAST CANCER CELL LINE MDA-MB-231 PREVENTING ANTICANCER DRUG METABOLISM
Objective: To investigate the interaction of LfcinB (Lactoferricin B) with GSTP1 (Glutathione S-Transferase P1) from human placental and breast cancer cell line MDA-MB-231.
Methods: We examined the interaction of Lfcin B with human placental GSTP1 and breast adenocarcinoma MD-MB-231 cell line. Enzyme activity of GSTP1 was measured with and without pre-incubation with Lfcin B. Kinetic variables were determined by incubating the enzyme reaction mixture with fixed GSH (reduced glutathione) concentration and varying CDNB (1-chloro-2, 4-dinitrobenzene) concentrations or fixed CDNB concentration and varying GSH concentrations.
Results: Lfcin B is a competitive inhibitor with respect to GSH binding site (G site) and noncompetitive inhibitor with respect to hydrophobic substrate unit (H site) of human placental GSTP1 enzyme. Lfcin B was also incubated with GSTP1 from breast adenocarcinoma MDA-MB-231 cell line. The activity of GSTP1 was much higher (0.2665 Î¼ mol/ml/min) in Lfcin B untreated MDA-MB-231 cell line, whereas MDA-MB-231 with Lfcin B treatment showed a very low activity (0.0254 Î¼ mol/ml/min).
Conclusion: Our Findings suggest that Lfcin B can inhibit the GSTP1 activity in human placental and MDA-MB-231 breast cancer cell lines, which may induce synergistic effects when used in combination with antineoplastic drugs that are substrates of GSTP1 enzyme. This combination will exert a double attack on cancers over expressing GSTP1, first sensitizing them to anticancer drugs by preventing their metabolism.
2. Hayes JD, Flangan JU, Jowsey IR. Glutathione s-transferases. Ann Rev Pharmacol Toxicol 2005;88:45-51.
3. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003;22:7369-75.
4. Eralp Y, Keskin S, AkÄ±ÅŸÄ±k E, AkÄ±ÅŸÄ±k E, Ä°ÄŸci A, MÃ¼slÃ¼manoÄŸlu M, et al. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2Î± expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Am J Clin Oncol 2013;36:215-23.
5. Vlachogeorgos GS, Manali ED, Blana E, Legaki S, Karagiannidis N, Polychronopoulus VS, et al. Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival. Cancer 2008;114:519-26.
6. Surowiak P, Materna V, Kaplenko I, SpaczyÅ„ski M, Dietel M, Lage H, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005;447:626-33.
7. Coles B, Anderson KE, Doerge DR, Churchwell MI, Lang NP, Kadlubar FF. Quantitative analysis of interindividual variation of glutathione s-transferase expression in human pancreas and the ambiguity of correlating genotype with phenotype. Cancer Res 2000;60:573-9.
8. Moral A, Palou J, Lafuente A, Molina R, Piulachs J, Castel T, et al. Immunohistochemical study of alpha, mu and pi class glutathione S transferase expression in malignant melanoma. MMM Group. Multidisciplinary Malignant Melanoma Group. Br J Dermatol 1997;136:345-50.
9. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic significance of glutathione S-transferase p1 expression and subcellular localization in human gliomas. Clin Cancer Res 1997;3:2253-61.
10. Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Mimic-Oka J. Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol 2009;6:281-9.
11. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH. Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 2005;65:9485-94.
12. Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer 1994;70:1144-9.
13. Singh S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol 2015;75:1-15.
14. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18:1321-34.
15. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65.
16. Singh S, Omkura T, Ali-Osman F. Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCÎ± enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Biochem Pharmacol 2010;80:1343-55.
17. Okamura T, Singh S, Buolamwini J. Tyrosine phosphorylation of the human glutathione S-Transferase P1 by epidermal growth factor receptor. J Biol Chem 2009;284:16979â€“89.
18. Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri AM. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 2010;500:116-22.
19. KD Tew. TLK-286:a novel glutathione S-transferase-activated prodrug. Expert Opin Invest Drugs 2005;14:1047-54.
20. Bidwell GL. Peptides for cancer therapy: a drug-development opportunity and a drug-delivery challenge. Ther Delivery 2012;3:609-21.
21. Jyothi Thundimathil. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012;967347:1-13.
22. J Pajaud, S Kumar, C Rauch, F Morel, C Aninat. Regulation of signal transduction by glutathione transferases. Int J Hepatol 2012;137676:1-11.
23. Burrow H, Kanwar RK, Mahidhara G. Effect of selenium-saturated bovine lactoferrin (Se-bLF) on antioxidant enzyme activities in human gut epithelial cells under oxidative stress. Anticancer Agents Med Chem 2011;11:762-71.
24. Yalcin S, Jensson H, Mannervik B. A set of inhibitors for discrimination between the basic isozymes of glutathione transferase in rat liver. Biochem Biophys Res Commun 1983;114:829-34.
25. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992;27:337â€“84.
26. Yin CM, Wong JH, Xia J, Ng TB. Studies on anticancer activities of lactoferrin and lactoferricin. Curr Protein Pept Sci 2013;6:492-503.
27. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide antimicrobial, antiviral, antitumor and immunological property. Cell Mol Life Sci 2005;62:2588-98.
28. Artym J. Antitumor and chemopreventive activity of lactoferrin. Postepy Hig Med Dosw 2006;60:352-69.
29. Agostoni CV, Bresson J-L, Fairweather-Tait S, Flynn A, Golly I, Korhonen H, et al. Scientific opinion on bovine lactoferrin EFSA panel on dietetic products, Nutrition and Allergies (NDA). EFSA J 2012;10(5):1-25.
30. Laborde E. Glutathione transferases as mediators of cell signaling pathways involved in cell proliferation and cell death. Cell Death Differ 2010;17:1373-80.
31. Karin M, Gallagher E. From JNK pay dir, jun kinases. Their biochemistry, physiology and clinical importance. IUBMB Life 2005;57:283-95.
32. Wu Y, Fan Y, Xue B, Luo L, Shen J, Zhang S, et al. Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 2006;25:5787-800.